» Articles » PMID: 19639412

What Do We Know About Neuropsychological Aspects of Schizophrenia?

Overview
Specialties Neurology
Psychology
Date 2009 Jul 30
PMID 19639412
Citations 105
Authors
Affiliations
Soon will be listed here.
Abstract

Application of a neuropsychological perspective to the study of schizophrenia has established a number of important facts about this disorder. Some of the key findings from the existing literature are that, while neurocognitive impairment is present in most, if not all, persons with schizophrenia, there is both substantial interpatient heterogeneity and remarkable within-patient stability of cognitive function over the long-term course of the illness. Such findings have contributed to the firm establishment of neurobiologic models of schizophrenia, and thereby help to reduce the social stigma that was sometimes associated with purely psychogenic models popular during parts of the 20th century. Neuropsychological studies in recent decades have established the primacy of cognitive functions over psychopathologic symptoms as determinants of functional capacity and independence in everyday functioning. Although the cognitive benefits of both conventional and even second generation antipsychotic medications appear marginal at best, recognition of the primacy of cognitive deficits as determinants of functional disability in schizophrenia has catalyzed recent efforts to develop targeted treatments for the cognitive deficits of this disorder. Despite these accomplishments, however, some issues remain to be resolved. Efforts to firmly establish the specific neurocognitive/neuropathologic systems responsible for schizophrenia remain elusive, as do efforts to definitively demonstrate the specific cognitive deficits underlying specific forms of functional impairment. Further progress may be fostered by recent initiatives to integrate neuropsychological studies with experimental neuroscience, perhaps leading to measures of deficits in cognitive processes more clearly associated with specific, identifiable brain systems.

Citing Articles

Predictors of Psychosocial Functioning Among Long-stay Schizophrenia Patients in a Malaysian Mental Institution.

Teo P, Koh E, Chong S Malays J Med Sci. 2025; 31(6):178-193.

PMID: 39830103 PMC: 11740817. DOI: 10.21315/mjms2024.31.6.14.


Neurocognitive and social cognitive correlates of social exclusion in psychotic disorders: a 20-year follow-up cohort study.

Peralta V, Sanchez-Torres A, Gil-Berrozpe G, de Jalon E, Moreno-Izco L, Peralta D Soc Psychiatry Psychiatr Epidemiol. 2024; 60(2):413-426.

PMID: 39090439 DOI: 10.1007/s00127-024-02742-x.


Association between increased BMI and cognitive function in first-episode drug-naïve male schizophrenia.

Deng X, Lu S, Li Y, Fang X, Zhang R, Shen X Front Psychiatry. 2024; 15:1362674.

PMID: 38505798 PMC: 10948420. DOI: 10.3389/fpsyt.2024.1362674.


Does cannabis affect cognitive functioning in patients with schizophrenia?.

Rachid H, Saif Z, Raoui S, Serhier Z, Agoub M Schizophr Res Cogn. 2024; 36:100299.

PMID: 38196922 PMC: 10772380. DOI: 10.1016/j.scog.2023.100299.


Moving from supported to independent living: what are the barriers and facilitators for individuals with psychosis?.

Poppe A, Tiles-Sar N, Konings S, Habtewold T, Bruggeman R, Alizadeh B Soc Psychiatry Psychiatr Epidemiol. 2024; 59(7):1243-1254.

PMID: 38189942 PMC: 11636980. DOI: 10.1007/s00127-023-02586-x.


References
1.
Walterfang M, Wood A, Reutens D, Wood S, Chen J, Velakoulis D . Morphology of the corpus callosum at different stages of schizophrenia: cross-sectional study in first-episode and chronic illness. Br J Psychiatry. 2008; 192(6):429-34. DOI: 10.1192/bjp.bp.107.041251. View

2.
Kee K, Kern R, Green M . Perception of emotion and neurocognitive functioning in schizophrenia: what's the link?. Psychiatry Res. 1998; 81(1):57-65. DOI: 10.1016/s0165-1781(98)00083-3. View

3.
Woodward N, Purdon S, Meltzer H, Zald D . A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005; 8(3):457-72. DOI: 10.1017/S146114570500516X. View

4.
Keefe R, Bilder R, Davis S, Harvey P, Palmer B, Gold J . Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007; 64(6):633-47. DOI: 10.1001/archpsyc.64.6.633. View

5.
Buchanan R, Freedman R, Javitt D, Abi-Dargham A, Lieberman J . Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull. 2007; 33(5):1120-30. PMC: 2632365. DOI: 10.1093/schbul/sbm083. View